UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2020

Commission File Number: 001-36515

 

 

Materialise NV

 

 

Technologielaan 15

3001 Leuven

Belgium

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒             Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):    ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):    ☐

This Form 6-K is incorporated by reference into the registrant’s Registration Statement on Form F-3 (File No. 333-213649).

 

 


Fourth Quarter and Full Year 2019 Financial Results

Except as otherwise required by the context, references to “Materialise,” “Company,” “we,” “us” and “our” are to Materialise NV and its subsidiaries.

Fourth Quarter 2019 Results

Total revenue for the fourth quarter of 2019 increased 3.5% to 50,712 kEUR compared to 49,014 kEUR for the fourth quarter of 2018.

Revenue from our Materialise Software segment increased 20.7% to 12,124 kEUR for the fourth quarter of 2019 from 10,044 kEUR for the same quarter last year.

Revenue from our Materialise Medical segment increased 14.1% to 17,209 kEUR for the fourth quarter of 2019 compared to 15,081 kEUR for the same period in 2018, including the impact of Engimplan, the Brazil-based manufacturer of orthopedic and cranio-maxillofacial (CMF) implants and instruments in which we acquired a 75% stake on August 1 2019. Compared to the fourth quarter of 2018, revenues from medical devices and services grew 16.9%. Revenues from our medical software grew 8.0% and deferred revenue from license and maintenance fees within the segment increased by 926 kEUR compared to the fourth quarter of 2018.

Revenue from our Materialise Manufacturing segment decreased 11.0% to 21,295 kEUR for the fourth quarter of 2019 from 23,926 kEUR for the fourth quarter of 2018.

Gross profit was 28,578 kEUR, or 56.4% of total revenue, for the fourth quarter of 2019 compared to 27,261 kEUR, or 55.6% of total revenue, for the fourth quarter of 2018.

Research and development (“R&D”), sales and marketing (“S&M”) and general and administrative (“G&A”) expenses increased, in the aggregate, 0.6% to 27,462 kEUR for the fourth quarter of 2019 from 27,290 kEUR for the fourth quarter of 2018.

Net other operating income increased to 1,474 kEUR compared to 810 kEUR for the fourth quarter of 2018.

Operating result increased to 2,589 kEUR from 781 kEUR for the fourth quarter of 2018.

Net financial result was (558) kEUR compared to (420) kEUR for the fourth quarter of 2018. The share in loss of joint venture amounted to (147) kEUR compared to (184) kEUR for the same period in 2018.

The fourth quarter of 2019 contained income tax expenses of (558) kEUR, compared to net tax income of 348 kEUR in the fourth quarter of 2018.

As a result of the above, net profit for the fourth quarter of 2019 was 1,327 kEUR, compared to net profit of 525 kEUR for the same period in 2018. Total comprehensive income for the fourth quarter of 2019, which includes exchange differences on translation of foreign operations, was 1,597 kEUR compared to 507 kEUR for the 2018 period.

Adjusted EBITDA increased to 7,749 kEUR from 6,052 kEUR. The Adjusted EBITDA margin (Adjusted EBITDA divided by total revenue) for the fourth quarter of 2019 was 15.3% compared to 12.3% for the fourth quarter of 2018.

Segment EBITDA from our Materialise Software segment increased to 5,026 kEUR from 2,969 kEUR while the segment EBITDA margin (segment EBITDA divided by segment revenue) was 41.5% compared to 29.6% for the prior-year period.

Segment EBITDA from our Materialise Medical segment was 3,468 kEUR compared to 3,593 kEUR while the segment EBITDA margin was 20.1% compared to 23.8% for the fourth quarter of 2018.

Segment EBITDA from our Materialise Manufacturing segment decreased to 1,761 kEUR from 1,983 kEUR while the segment EBITDA margin remained flat at 8.3%.

Full Year 2019 Results

Total revenues for the year ended December 31, 2019 increased 6.5% to 196,679 kEUR compared to 184,721 kEUR for the year ended December 31, 2018. Excluding the 2,437 kEUR revenue impact of Engimplan, revenues increased 5.2%.


Revenues from our Materialise Software segment increased 11.4% to 41,654 kEUR for the year ended December 31, 2019 compared to 37,374 kEUR for the year ended December 31, 2018.

Revenues from our Materialise Medical segment grew by 16.4% for the year ended December 31, 2019 to 60,809 kEUR from 52,252 kEUR for the year ended December 31, 2018. Medical software growth was 13.9%, and revenues from medical devices and services increased 17.6%, including Engimplan’s impact.

Revenues from our Materialise Manufacturing segment decreased 0.8% to 94,156 kEUR for the year ended December 31, 2019 from 94,956 kEUR for the year ended December 31, 2018.

Operating profit improved 1,852 kEUR to 7,016 kEUR for the year ended December 31, 2019 from 5,164 kEUR. The increased net financial expenses of 1,070 kEUR and increased income tax expenses of 2,170 kEUR impacted our net result. Accordingly, net profit decreased to 1,724 kEUR for 2019 compared to 3,027 kEUR for 2018.

At December 31, 2019, we had cash and equivalents of 128,897 kEUR compared to 115,506 kEUR at December 31, 2018. Gross debt amounted to 127,939 kEUR (including 5,160 kEUR of lease liabilities recognized under the new accounting standard IFRS 16), compared to 106,037 kEUR at December 31, 2018.

Adjusted EBITDA for the year ended December 31, 2019 was 26,656 kEUR, an increase of 13.3% compared to 23,526 kEUR for the year ended December 31, 2018. The Adjusted EBITDA margin increased to 13.6% from 12.7% in 2018.

Segment EBITDA from our Materialise Software segment was 33.2% in 2019 compared to 30.9% in 2018.

Segment EBITDA from our Materialise Medical segment was 17.7% in 2019, compared to 19.6% in 2018.

Segment EBITDA from our Materialise Manufacturing segment increased from 11.4% for 2018 to 12.9% in 2019.

Cash flow from operating activities for the year ended December 31, 2019 was 28,402 kEUR compared to 28,320 kEUR in the year ended December 31, 2018. Total capital expenditures for the year ended December 31, 2019 amounted to 15,665 kEUR. This amount included 1,070 kEUR of capitalized R&D expenditures from medical programs.

Net shareholders’ equity at December 31, 2019 was 142,675 kEUR compared to 135,989 kEUR at December 31, 2018.

Note on Comparability

As a result of the implementation of the new accounting standard IFRS 16, we recognized additional lease assets and liabilities in the amount of 4,998 kEUR at January 1, 2019. At the end of the year ended December 31, 2019, the total commitment of lease assets and liabilities amounted to 5,025 kEUR. Our Adjusted EBITDA for the year ended December 31, 2019 was affected positively by the new standard as a result of the rental payments decrease of 2,580 kEUR; however, our operating profit was impacted by (18) kEUR as depreciation expenses increased by 2,597 kEUR. For the fourth quarter of 2019 our Adjusted EBITDA was affected positively by 641 kEUR, while our operating profit was impacted by (93) kEUR and depreciation expenses increased by 735 kEUR.

Non-IFRS Measures

Materialise uses EBITDA and Adjusted EBITDA as supplemental financial measures of its financial performance. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of loss in a joint venture and depreciation and amortization. Adjusted EBITDA is determined by adding non-cash stock-based compensation expenses and acquisition-related expenses of business combinations to EBITDA. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of long-term investment and financing decisions, rather than the performance of the Company’s day-to-day operations. As compared to net profit, these measures are limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the Company’s business, or the charges associated with impairments. Management evaluates such items through other financial measures such as capital expenditures and cash flow provided by operating activities. The Company believes that these measurements are useful to measure a company’s ability to grow or as a valuation measurement. The Company’s calculation of EBITDA and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBITDA and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The Company’s presentation of EBITDA and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items.


Exchange Rate

This document contains translations of certain euro amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from euros to U.S. dollars in this document were made at a rate of EUR 1.00 to USD 1.117319, the reference rate of the European Central Bank on December 31, 2019.

About Materialise

Materialise incorporates 30 years of 3D printing experience into a range of software solutions and 3D printing services, which form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines one of the largest groups of software developers in the industry with one of the largest 3D printing facilities in the world.

Cautionary Statement on Forward-Looking Statements

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations, plans, objectives, strategies and prospects, both financial and business. When used in this report, the words “estimate,” “expect,” “anticipate,” “project,” “plan,” “intend,” “believe,” “forecast,” “will,” “may,” “could,” “might,” “aim,” “should,” and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this report. These expectations, beliefs and projections are expressed in good faith and the Company believes there is a reasonable basis for them. However, the Company cannot offer any assurance that our expectations, beliefs and projections will actually be achieved. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. All of the forward-looking statements are subject to risks and uncertainties that may cause the Company’s most recent actual results to differ materially from our expectations, including risk factors described in the Company’s most recent annual report on Form 20-F filed with the U.S. Securities and Exchange Commission. There are a number of risks and uncertainties that could cause the Company’s actual results to differ materially from the forward-looking statements contained in this report.

The Company is providing this information as of the date of this report and does not undertake any obligation to update any forward-looking statements contained in this report as a result of new information, future events or otherwise, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

 


 

Consolidated income statements (Unaudited)

 

     For the three months ended
December 31,
            For the twelve
months ended
December 31,
 

In 000, except per share amounts

   2019      2019      2018             2019      2018  
     U.S.$                             

Revenue

     56,660        50,712        49,014           196,679        184,721  

Cost of sales

     (24,730)        (22,134)        (21,753)           (86,972)        (82,299)  

Gross profit

     31,930        28,578        27,261           109,707        102,422  

Gross profit as % of revenue

     56.4%        56.4%        55.6%           55.8%        55.4%  
                 

Research and development expenses

     (6,633)        (5,937)        (5,335)           (23,348)        (22,416)  

Sales and marketing expenses

     (15,857)        (14,192)        (12,571)           (52,989)        (46,303)  

General and administrative expenses

     (8,194)        (7,333)        (9,384)           (31,786)        (32,310)  

Net other operating income (expenses)

     1,646        1,474        810           5,432        3,771  

Operating (loss) profit

     2,893        2,589        781           7,016        5,164  
                 

Financial expenses

     (1,156)        (1,035)        (1,308)           (3,682)        (4,864)  

Financial income

     533        477        888           1,377        3,627  

Share in loss of joint venture

     (164)        (147)        (184)           (392)        (475)  

(Loss) profit before taxes

     2,106        1,885        177           4,319        3,452  
                 

Income taxes

     (623)        (558)        348           (2,595)        (425)  

Net (loss) profit for the period

     1,483        1,327        525           1,724        3,027  

  Net (loss) profit attributable to:

                 

The owners of the parent

     1,475        1,321        525           1,646        3,027  

Non-controlling interest

     8        7                  79         
                 

Earnings per share attributable to owners of the parent

                 

Basic

     0.03        0.03        0.01           0.03        0.06  

Diluted

     0.03        0.03        0.01           0.03        0.06  
                 

Weighted average basic shares outstanding

     52,891        52,891        52,882           52,891        49,806  

Weighted average diluted shares outstanding

     53,797        53,797        53,761           53,779        50,609  


 

Consolidated statement of comprehensive income (Unaudited)

 

     For the three months ended
December 31,
            For the twelve
months ended
December 31,
 
In 000        2019              2019              2018                     2019              2018      
     U.S.$                             
                 

Net profit (loss) for the period

     1,483        1,327        525           1,724        3,027  

  Other comprehensive income

                 

Exchange difference on translation of foreign operations

     165        148        (18)           245        (47)  

  Other comprehensive income (loss), net of taxes

     165        148        (18)           245        (47)  

Total comprehensive income (loss) for the year, net of taxes

     1,648        1,475        507           1,969        2,980  

Total comprehensive income (loss) attributable to:

                 

  The owners of the parent

     1,784        1,597        507           2,102        2,980  

  Non-controlling interest

     (136)        (122)                  (133)         


 

Consolidated statement of financial position (Unaudited)

 

     As of
December
31,
     As of
December
31,
 
In 000    2019      2018  
           

Assets

     

Non-current assets

     

Goodwill

     20,174        17,491  

Intangible assets

     27,395        26,326  

Property, plant & equipment

     100,917        92,537  

Investments in joint ventures

     39     

Deferred tax assets

     192        315  

Other non-current assets

     9,391        7,237  

Total non-current assets

     158,108        143,906  

Current assets

     

Inventories & contracts in progress

     12,696        9,986  

Trade receivables

     40,322        36,891  

Other current assets

     9,271        6,936  

Cash and cash equivalents

     128,897        115,506  

Total current assets

     191,186        169,319  

Total assets

     349,294        313,225  


 

 

     As of
December
31,
     As of
December
31,
 
In 000    2019      2018  
           

Equity and liabilities

     

Equity

     

Share capital

     3,066        3,050  

Share premium

     138,090        136,637  

Consolidated reserves

     (195)        (1,848)  

Other comprehensive loss

     (1.394)        (1,850)  

Equity attributable to the owners of the parent

     139,567        135,989  

Non-controlling interest

     3,107         

Total equity

     142,675        135,989  

Non-current liabilities

     

Loans & borrowings

     111,100        92,440  

Deferred tax liabilities

     5,747        6,226  

Deferred income

     5,031        4,587  

Other non-current liabilities

     696        868  

Total non-current liabilities

     122,575        104,121  

Current liabilities

     

Loans & borrowings

     16,839        13,598  

Trade payables

     18,516        18,667  

Tax payables

     3,363        2,313  

Deferred income

     27,641        23,195  

Other current liabilities

     17,686        15,342  

Total current liabilities

     84,044        73,115  

Total equity and liabilities

     349,294        313,225  


 

Consolidated statement of cash flows (Unaudited)

 

     For the twelve months ended
December 31,
 
in 000    2019      2018  
     €            €        

Operating activities

     

Net profit for the period

     1,724        3,027  

Non-cash and operational adjustments

     

Depreciation of property, plant & equipment

     14,339        12,223  

Amortization of intangible assets

     4,859        5,064  

Share-based payment expense

     (9)        1,075  

Loss (gain) on disposal of property, plant & equipment

     165        (83)  

Movement in provisions

     138        5  

Movement reserve for bad debt

     121        1,293  

Financial income

     (1,383)        (581)  

Financial expense

     3,693        2,172  

Impact of foreign currencies

     (176)        (299)  

Share in loss of a joint venture (equity method)

     392        475  

(Deferred) income taxes

     2,593        425  

Other

     64        (105)  

Working capital adjustment & income tax paid

     

Increase in trade receivables and other receivables

     216        (3,156)  

Decrease (increase) in inventories

     (745)        812  

Increase in trade payables and other payables

     4,196        7,341  

Income tax paid & interest received

     (1,783)        (1 368)  

Net cash flow from operating activities

     28,402        28,320  


 

 

     For the twelve months ended
December 31,
 
in 000    2019      2018  
     €            €        

Investing activities

     

Purchase of property, plant & equipment

     (13,472)        (18,270)  

Purchase of intangible assets

     (2,193)        (1,836)  

Proceeds from the sale of property, plant & equipment & intangible assets (net)

     278        281  

Other equity investments in non-listed entities

     (281)        (2,671)  

Investments in joint ventures

     (875)        --  

Convertible loan to third party

     (2,743)         

Investments in subsidiary, net of cash acquired

     (6,331)         

Interest received

     -        363  

Net cash flow used in investing activities

     (25,617)        (22,133)  
     

Financing activities

     

Proceeds from loans & borrowings

     29,000        32,554  

Repayment of loans & borrowings

     (12,126)        (18,820)  

Repayment of finance leases

     (5,283)        (3,102)  

Capital increase in parent company

     1,268        60,489  

Direct attributable expense of capital increase

            (4,003)  

Interest paid

     (2,286)        (1,733)  

Other financial income (expense)

     208        (150)  

Net cash flow from (used in) financing activities

     10,782        65,235  
     

Net increase of cash & cash equivalents

     13,566        71,422  

Cash & cash equivalents at beginning of the year

     115,506        43,175  

Exchange rate differences on cash & cash equivalents

     -173        908  

Cash & cash equivalents at end of the period

     128,897        115,506  


 

Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited)

 

     For the three months
    ended December 31,    
            For the twelve months
    ended December 31,    
 
In 000    2019      2018             2019      2018  
                            
              

Net profit (loss) for the period

     1,327        525           1,724        3,027  
              

Income taxes

     (558)        (348)           2,595        425  

Financial expenses

     1,035        1,308           3,682        4,864  

Financial income

     (477)        (888)           (1,377)        (3,627)  

Share in loss of joint venture

     147        184           392        475  

Depreciation and amortization

     5,115        4,753           19,198        17,287  
              

EBITDA

     7,705        5,534           26,214        22,451  
              

Non-cash stock-based compensation expense (1)

     44        518           302        1,075  

Acquisition-related expenses of business combinations (2)

                  140         
              

ADJUSTED EBITDA

     7,749        6,052           26,656        23,526  

 

  (1)

Non-cash stock-based compensation expense represents the cost of equity-settled and cash-settled share-based payments to employees.

 

  (2)

Acquisition-related expenses of business combinations represents expenses incurred in connection with the Engimplan acquisition.


 

Segment P&L (Unaudited)

 

In 000    Materialise
Software
     Materialise
Medical
     Materialise
Manu-
facturing
     Total
segments
     Unallocated
(1)(2)
     Consoli-
dated
 
                               
                 

For the three months ended December 31, 2019

                 

Revenues

     12,124        17,209        21,295        50,628            84        50,712  

Segment EBITDA

       5,026          3,468          1,761        10,255        (2,506)          7,749  
                 

Segment EBITDA %

      41.5%         20.1%           8.3%         20.3%            15.3%  
                 

For the three months ended December 31, 2018

                 

Revenues

     10,044        15,081        23,926        49,051            (37)        49,014  

Segment EBITDA

     2,969          3,593          1,983          8,545        (2,492)          6,052  
                 

Segment EBITDA %

      29.6%         23.8%           8.3%         17.4%            12.3%  

 

 

 

                             
In 000    Materialise
Software
     Materialise
Medical
     Materialise
Manu-
facturing
     Total
segments
     Unallocated
(1)(2)
     Consoli-
dated
 
                               
                 

For the twelve months ended December 31, 2019

                 

Revenues

     41,654        60,809        94,156        196,619              61        196,679  

Segment EBITDA

     13,812        10,774        12,154          36,740        (10,526)          26,656  
                 

Segment EBITDA %

     33.2%        17.7%        12.9%        18.7%           13.6%  
                 

For the twelve months ended December 31, 2018

                 

Revenues

     37,374        52,252        94,956        184,582            139        184,721  

Segment EBITDA

     11,536        10,252        10,785          32,573        (10,122)          23,526  
                 

Segment EBITDA %

     30.9%        19.6%        11.4%        17.6%           12.7%  

 

  (1)

Unallocated Revenues consists of occasional one-off sales in our core competencies not allocated to any of our segments.

 

  (2)

Unallocated segment EBITDA consists of corporate research and development, corporate headquarter costs and other operating income (expense), and the added non-cash stock-based compensation expenses and acquisition related expenses of business combinations that are included in Adjusted EBITDA.


 

Reconciliation of Net Profit (Loss) to Segment EBITDA (Unaudited)

 

     For the three months
    ended December 31,    
            For the twelve months
    ended December 31,    
 
In 000    2019      2018             2019      2018  
                            
              

Net profit (loss) for the period

     1,327        525           1,724        3,027  

Income taxes

     558        (348)           2,595        425  

Financial cost

     1,035        1,308           3,682        4,864  

Financial income

     (477)        (888)           (1,377)        (3,627)  

Share in loss of joint venture

     147        184           392        475  
              

Operating profit

     2,590        781           7,016        5,164  
              

Depreciation and amortization

     5,115        4,753           19,198        17,287  

Corporate research and development

     456        444           1,798        1,913  

Corporate headquarter costs

     2,573        2,844           10,547        10,358  

Other operating income (expense)

     (479)        (277)           (1,819)        (2,149)  
              

Segment EBITDA

     10,255        8,545           36,740        32,573  


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

MATERIALISE NV

By:

 

 /s/ Wilfried Vancraen

Name:

 

 Wilfried Vancraen

Title:

 

 Chief Executive Officer

Date: March 4, 2020

Materialise NV (NASDAQ:MTLS)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Materialise NV Charts.
Materialise NV (NASDAQ:MTLS)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Materialise NV Charts.